Viemed Healthcare (VMD) Q3 2026 earnings review
Viemed's sleep business grows fast, but its profit plan shrinks
Viemed Healthcare, a provider of in-home respiratory and sleep equipment, restored its profit margins while adding sleep patients at a record pace. Sales from businesses owned a year ago grew 12% to $81 million now that last year's Lehan acquisition sits in both periods, and chief executive Casey Hoyt said early-year overhead investments are paying off. However, management trimmed the top end of its full-year operating profit plan by $2 million, which by our math still requires margins to reach 24% in the fourth quarter.
| Sales from businesses owned a year ago | $80.7M +12.2% from a year ago |
|---|---|
| Adjusted EBITDA margin | 21.1% up from 17.6% last quarter, down from 22.4% a year ago |
| PAP sleep therapy patients | 43,861 +37.5% from a year ago |
| Full-year Adjusted EBITDA outlook | Cut $1M at middle narrowed to $64–66M from $64–68M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because rebounding third-quarter margins and record sleep patient additions were offset by a second straight trim to the full-year profit outlook. On the negative side, active ventilator patient counts slipped by 83 after bouncing back in the second quarter, and a $9 million buildup in unpaid customer bills reduced free cash flow.
The question now is whether shifting toward sleep and maternal supply sales improves cash generation or permanently lowers profit margins. One view is that lower equipment spending will boost free cash flow once billing delays clear; the other is that supply sales dilute margins and tie up working capital. Fourth-quarter profit margins and cash collections will settle it.
🐂 Bull Case
Sleep Patient Additions Reached a Record High
Viemed provides positive airway pressure (PAP) machines for sleep apnea and ships replacement masks and tubing to patients at home. The company has used new intake software to sign up sleep patients faster without adding back-office staff. In the third quarter, PAP therapy patients jumped 16.0% from last quarter to 43,861, while sleep resupply patients rose 10.5% to 40,918.
- Quarterly PAP patient additions: 6,036 by our math, the largest single-quarter gain on record
- Like-for-like comparison: up from 3,166 additions a year ago by our math, stripping out the 2,465 patients acquired with Lehan
- Sleep share of total revenue: 23%, up from 21% a year ago
This surge matters because new PAP patients become recurring buyers of replacement supplies three to six months later. Because Viemed ships those supplies directly to homes without buying rental fleet equipment, the sleep business requires very little capital. Furthermore, management achieved this record patient intake while reducing total selling, general and administrative expenses from the second quarter.
What to watch: sleep resupply patient additions in the fourth quarter and first quarter of 2027. A similar jump in resupply orders would confirm that this quarter's record machine setups are turning into recurring supply sales.
Clean Revenue Growth Topped 12% After Lapping Lehan
Viemed bought Lehan's Medical Equipment on July 1, 2025, adding breast pumps and maternal supplies in a line it calls Women's Health. Because that deal closed at the start of last year's third quarter, this quarter gives the first clean year-over-year comparison. Chief executive Casey Hoyt said "achieving double-digit revenue growth underscores the strength of our increasingly diversified platform".
Total revenue rose 12.2% from a year ago to $80.7 million, driven by a 23.7% jump in equipment and supply sales to $19.4 million. Women's Health held steady at 8% of revenue, up from 6% a year ago, as Viemed rolls the service out across its national insurance contracts. Because sales and services now make up 32% of revenue, the business needs less rental equipment, allowing management to cut its full-year capital spending plan a third time.
What to watch: fourth-quarter revenue against the $83.8 million implied by the middle of the full-year outlook. Hitting that mark would prove the company can sustain 10% underlying sales growth without acquisition boosts.
🐻 Bear Case
Margins Rebounded, But the Full-Year Profit Plan Was Trimmed
Adjusted EBITDA — operating profit before depreciation, stock pay and acquisition costs — fell to 17.6% of revenue in the second quarter when overhead costs rose. In the third quarter, Hoyt noted that "Adjusted EBITDA grew 24%, significantly outpacing revenue growth and demonstrating improved operating leverage." Selling, general and administrative expenses (day-to-day overhead and sales pay) dropped to 44.0% of revenue from 47.5% last quarter, lifting the Adjusted EBITDA margin to 21.1%.
Even so, the profit margin remains 1.3 percentage points below the 22.4% earned a year ago because equipment sales carry lower margins than ventilator rentals. More importantly, Viemed cut the top end of its full-year Adjusted EBITDA outlook by $2 million, to $64–66 million, one quarter after cutting the range by $1 million. By our math, hitting the middle of the lowered plan still requires a 23.8% margin in the fourth quarter.
What to watch: fourth-quarter Adjusted EBITDA margin against the 23.8% implied by the full-year plan. A shortfall would show that the growing share of sleep and maternal sales caps the company's peak profitability.
Active Ventilator Patient Counts Shrank After the Second-Quarter Bounce
Home ventilator rentals remain Viemed's financial anchor, bringing in 46.4% of total revenue at high margins. After Medicare introduced stricter rules for ventilator coverage in June 2025, Viemed's active patient count shrank for two quarters before rebounding by 546 patients in the second quarter of 2026. Bulls argued that this second-quarter jump proved the company was winning market share as smaller rivals struggled with the new paperwork.
In the third quarter, however, the period-end ventilator count slipped by 83 patients from June to 12,552, leaving the patient base up just 1.5% from a year ago. Ventilator rental revenue still rose 7.4% from a year ago to $37.5 million on "higher average patient volumes" and an inflation rate adjustment, earning $2,970 per average patient by our math. Because period-end counts lead next quarter's average billing base, the third-quarter dip stalls the recovery.
What to watch: year-end active ventilator patients in the fourth-quarter report. A second consecutive quarterly decline would show that Medicare's stricter coverage rules are still limiting patient additions.
Unpaid Customer Bills Held Back Free Cash Flow
Viemed argues that shifting toward sleep and maternal supplies will boost free cash flow — operating cash left after net equipment purchases — because those lines need less capital. In the third quarter, net capital spending was $7.5 million, or 9.2% of revenue. Yet free cash flow dropped to $4.0 million, down from $8.6 million in the second quarter and $12.4 million a year ago.
- Accounts receivable (unpaid bills): $34.9 million, up 27.3% from a year ago against 12.2% revenue growth
- Nine-month cash drain from unpaid bills: $9.3 million, compared with $0.7 million in the first nine months of 2025
- Prepaid expenses and other current assets: $10.2 million, up $4.4 million from June by our math
The cash shortfall happened because cash stayed tied up on the balance sheet rather than reaching the bank account. When receivables and prepaids grow more than twice as fast as sales, lower equipment spending does not turn into spendable cash.
What to watch: fourth-quarter accounts receivable and operating cash flow. A drop in receivables would release the trapped cash and restore free cash flow conversion.
Risks this quarter didn't answer
Several standing legal, accounting and product-level questions received no update in the third-quarter earnings release or investor slides.
- Medicare audit appeal: no update on the $2.2 million Qlarant audit dispute carried in prepaid assets after an unfavorable June judge's ruling; the quarterly 10-Q filing will show if Viemed recorded a loss reserve.
- Phantom-stock pay swings: the release does not state how much cash-settled phantom stock expense hit overhead costs this quarter; the 10-Q footnote will disclose the exact dollar figure.
- Product-line profit margins: management again gave rounded revenue shares for sleep and Women's Health without disclosing their standalone profit margins.
- Credit facility refinancing and post-2028 bidding: no new details on refinancing credit lines due in November 2027 or on Medicare competitive bidding rules after 2028.
👓 Other Themes
Medicare Rules and Rate Hikes Support the Core Business
Government healthcare policy remains steady for Viemed's core respiratory equipment. In its investor presentation, the company highlighted that Medicare payment rates rose 2.0% to 2.8% in January 2026 to match inflation. In addition, the Centers for Medicare and Medicaid Services excluded Viemed's core ventilator and respiratory categories from its competitive bidding program, which is not scheduled to restart until 2028.
💲 Other KPIs
Diluted shares rose 1.7% from a year ago and 0.2% from the second quarter. Viemed bought back 115,000 shares for $1.0 million during the quarter, bringing nine-month repurchases to 795,802 shares for $7.5 million. However, employee stock grants and option exercises outpaced the buybacks, leaving the diluted share count higher than last year.
Long-term debt fell from $6.37 million in June and $11.29 million at the end of 2025. The home healthcare provider repaid $2.1 million of its term loan during the third quarter and $7.6 million over the first nine months. With $9.7 million in cash, Viemed holds more cash than total debt.
Gross margin — revenue left after direct equipment and clinical service costs — edged down 0.2 percentage points from 57.5% a year ago and 0.4 points from 57.7% in the second quarter. The slight dip reflects faster growth in sleep and maternal supply sales, which carry lower gross margins than ventilator rentals.
🔮 Guidance
Raised. Viemed lifted the bottom of its full-year sales plan by $2 million, putting the middle of the range at $318 million, or 17.7% growth for the year. By our math, that leaves $83.8 million for the fourth quarter, up 10.0% from a year ago and 3.9% from the third quarter. It is the third straight quarter management has raised the low end by $2 million, moving the middle up by $1 million each time.
Cut. The firm lowered the top end of its full-year operating profit outlook by $2 million, moving the middle of the range down $1 million to $65 million, or 5.9% growth over 2025. By our math, reaching $65 million requires $19.9 million in the fourth quarter, up 9.4% from a year ago and equal to a 23.8% margin. It is the second straight quarter management has reduced the middle of this range by $1 million.
Cut. Management lowered its equipment spending forecast by 0.75 percentage points at the middle of the range to 8.5% of sales, citing "reduced capital intensity as less capital-intensive product and service offerings contribute a greater share of revenue". By our math, after spending 8.6% in the first nine months, the outlook implies 8.1% in the fourth quarter. This is the third reduction this year: -1.0 point, -0.5 points, -0.75 points.
❓ Key Questions
Why did accounts receivable and prepaid assets jump in Q3?
Unpaid customer bills rose $9.3 million over nine months to $34.9 million, while prepaid expenses jumped $4.4 million in the third quarter alone. Investors need to know if billing holds in sleep or Women's Health caused the buildup and when collections will catch up.
Why did active ventilator patient counts dip by 83?
After adding 546 ventilator patients in the second quarter, the active count fell by 83 in the third quarter to 12,552. Management should explain whether higher patient turnover or stricter insurance documentation rules caused the pullback.
What drives the implied 23.8% fourth-quarter profit margin?
Reaching the middle of the full-year Adjusted EBITDA plan requires the margin to rise from 21.1% in the third quarter to 23.8% in the fourth. Investors should ask how much comes from lower overhead versus higher-margin seasonal revenue.
What is the status of the $2.2 million Medicare audit?
Viemed lost an administrative judge's ruling in June over a $2.2 million Medicare audit payment that it carried as a prepaid asset. With the 10-Q not yet filed, management should clarify the next appeal step and whether a loss reserve is needed.